Substituted bicyclic compounds

US11701373B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11701373-B2
Application numberUS-202117307138-A
CountryUS
Kind codeB2
Filing dateMay 4, 2021
Priority dateAug 20, 2014
Publication dateJul 18, 2023
Grant dateJul 18, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R 1 is —OH or —OP(O)(OH) 2 , and X 1 , X 2 , X 3 , R 2 , R 2a , R a , R b , and R c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (IV): or a salt thereof, wherein: R 1 is —OH or —OP(O)(OH) 2 ; R 2a is —C(O)(CH 2 ) 0-4 C(R x ) 3 ; each R x is independently H; and each R b is independently H. 2. The compound according to claim 1 having the structure of Formula (IVc): or a salt thereof. 3. The compound according to claim 1 or a salt thereof. 4. The compound according to claim 1 , wherein said compound is: 5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein R 1 is —OH.

Assignees

Inventors

Classifications

  • A61K31/695Primary

    Silicon compounds · CPC title

  • having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title

  • A61K31/137Primary

    Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

  • Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)} · CPC title

  • having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11701373B2 cover?
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R 1 is —OH or —OP(O)(OH) 2 , and X 1 , X 2 , X 3 , R 2 , R 2a , R a , R b , and R c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such comp…
Who is the assignee on this patent?
Bristol Myers Squibb Co
What technology area does this patent fall under?
Primary CPC classification A61K31/695. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).